Biocontainment design considerations for biopharmaceutical facilities |
| |
| Authors: | Steven R Miller Don Bergmann |
| |
| Institution: | (1) SmithKline Beecham Pharmaceuticals, P.O. Box 1539, 19406 King of Prussia, PA, USA |
| |
| Abstract: | Summary This article highlights biocontainment design considerations for biopharmaceutical manufacturing facilities. The major focus of this report is on industry's use and interpretation of the regulations with specific design recommendations for a Biosafety Level 2 — Large-Scale physical containment level as described by the National Institutes of Health Guidelines. |
| |
| Keywords: | Biosafety Biocontainment Biopharmaceutical design Biological inactivation |
| 本文献已被 SpringerLink 等数据库收录！ |
